Skip to content

Cognitive impairment and imaging prediction model after intravenous thrombolysis in mild ischemic stroke

Cognitive impairment and imaging prediction model after intravenous thrombolysis in mild ischemic stroke

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300071261
Enrollment
Unknown
Registered
2023-05-09
Start date
2023-05-01
Completion date
Unknown
Last updated
2023-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive impairment after stroke

Interventions

Intravenous thrombolysis group:N/A
Double antibody group:N/A

Sponsors

Zhongnan Hospital of Wuhan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 50-75 years, right-handed. 2. First acute ischemic stroke, NIHSS=9 years). 5. Voluntarily participate in this survey and follow-up survey, and sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Pre-disease mRS > 1 score, history of cognitive impairment; 2. History of psychoactive drug abuse; 3. Have been clearly diagnosed malignant tumor, vital organ failure, life expectancy is less than 3 years; 4. Severe vision or hearing impairment or aphasia may not cooperate with neuropsychological evaluators; 5. Other serious physical diseases that affect cognitive tests, such as coma, epilepsy, hypothyroidism, hypoxemia, etc.; 6. Congenital intellectual disability, history of brain trauma or serious nervous system or mental illness; 7. Imaging changes related to other central nervous system diseases were found on MRI; 8. Head CT or head MRI indicated large cerebral infarction (infarct area > 1/3 middle cerebral artery blood supply area); DWI does not display high signal. * Other neurological disorders: Parkinson's disease, epilepsy, myasthenia, multiple sclerosis, motor neurone disease, immune-related encephalomyelopathy, etc. * Severe mental illness: anxiety disorder, depression, schizophrenia, bipolar disorder, mental retardation, etc. that is diagnosed or controlled by medication.

Design outcomes

Primary

MeasureTime frame
cognitive fuction;

Secondary

MeasureTime frame
structural brain network;brain atrophy;

Countries

China

Contacts

Public ContactZhang Junjian

Zhongnan Hospital of Wuhan University

wdsjkx@163.com+86 139 8622 5751

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026